Abstract. Treatment of platelets with thrombin was shown previously to induce rapid changes in tyrosine phosphorylation of several platelet proteins. In this report, we demonstrate that a variety of agonists which induce platelet aggregation also stimulate tyrosine phosphorylation of three proteins with apparent molecular masses of 84, 95, and 97 kD. Since platelet aggregation requires the agonist-induced activation of an integrin receptor (GP IIb-IRa) as well as the binding of fibrinogen to this receptor, we examined the relationship between tyrosine phosphorylation and the function of GP lib-Ilia. When platelets were examined under conditions that either precluded the activation of GP lib-iRa (prior disruption of the complex by EGTA at 37°C) or the binding of fibrinogen (addition of RGDS or an inhibitory rnAb), tyrosine phosphorylation of the 84-, 95-, and 97-kD proteins was not observed. However, although both GP lib-iRa activation and fibrinogen binding were necessary for tyrosine phosphorylation, they were not sufficient since phosphorylation was observed only under conditions in which the activated platelets were stirred and allowed to aggregate. In contrast, tyrosine phosphorylation was not dependent on another major platelet response, dense granule secretion. Furthermore, granule secretion did not require tyrosine phosphorylation of this set of proteins. These experiments demonstrate that agonistinduced tyrosine phosphorylation is linked to the process of GP l/b-IRa-mediated platelet aggregation. Thus, tyrosine phosphorylation may be required for events associated with platelet aggregation or for events that follow aggregation.
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LATELETS are an excellent model system in which to study the mechanisms of signal transduction. Physiological agonists elicit a variety Of cellular responses including shape change, aggregation, granule secretion, and generation of membrane procoagulant activity. The transduction mechanisms that lead to these platelet responses inelude activation of guanine nueleotide-binding proteins, hydrolysis of membrane phospholipids, release and metabolism of arachidonic acid, influx and mobilization of calcium, and stimulation of protein phosphorylation (Siess, 1989; Brass et ai., 1990) .
The role of protein phosphorylation in platelet responses has been the subject of intensive study (Kroll and Schafer, 1989; Siess, 1989) . Many of the phosphorylation events observed upon platelet stimulation have been attributed to the actions of protein kinase C and myosin light chain kinase, both of which are serine/threonine-specific protein kinases. Recently, several tyrosine-speeific protein kinases have been detected in platelets. These include the cellular src gene product (Golden et al., 1986; Varshney et al., 1986; Presek et al., 1988; Rendu et al., 1989) , the ceUularfyn gene prod-uct (Horak et al., 1989) , and several unidentified kinases (Nakamura et al., 1985 (Nakamura et al., , 1988 . Moreover, a number of proteins are phosphorylated on tyrosine residues after platelet activation by thrombin and other platelet agonists (Ishihara et al., 1985; Ferrell and Martin, 1988, 1989; Golden and Brugge, 1989; Nakamura and Yamarnura, 1989) . The identity of the protein-tyrosine kinases and their substrates and the precise role of tyrosine pbosphorylation during platelet activation remain to be determined. Recently, Ferrell and Martin have shown that thrombin-induced tyrosine phosphorylation of several platelet proteins appears to require ligand binding to the platelet membrane glycoprotein (GP) ~ IIb-llla complex (Ferrell and Martin, 1989) , a member of the integrin family of adhesion receptors (Pytela et al., 1986; Hynes, 1987) .
GP Hb-iRa plays a critical role in platelet aggregation, a process that requires the agonist-induced binding of fibrinogen to GP IIb-iRa (Bennett and Vilaire, 1979; Plow and Ginsberg, 1989) . Agonists activate GP Hb-I~a, presumably by inducing a eonformational change that exposes a binding site for fibrinogen, thus enabling fibrinogen to bind in a calcium-dependent manner (Shattil et al., 1985a (Shattil et al., , 1986 .
Once fibrinogen is bound, platelets can aggregate, provided that the cells physically interact. Several lines of evidence suggest that fibrinogen-mediated aggregation is coupled to other platelet response pathways. First, the activated form of GP Ilb-IIIa has been implicated in platelet Na+/H + exchange and in activation of phospholipase A2 (Swear et al., 1985 (Swear et al., , 1986 Banga et al., 1986) . Second, when platelets are stimulated by so-called "weak" agonists such as ADP or epinephrine, platelet aggregation is required for arachidonic acid metabolism, thromboxane A2 synthesis, and granule secretion (Huang and Detwiler, 1986) . In contrast, "strong" agonists, such as thrombin or collagen can induce thromboxane A2 synthesis and granule secretion independent of platelet aggregation. However, even in the case of thrombin or collagen, aggregation is required to promote association of GP Hb-IHa with the Triton-insoluble membrane cytoskeleton (Phillips et al., 1980; Fox, 1987) and to activate calcium-dependent proteases (callpalns) within the cell (Fox, 1987) .
Given the presence of multiple-protein tyrosine kinases in platelets, the rapid induction of tyrosine phosphorylation after platelet activation, and the central role of GP Hb-iRa in platelet function, we sought to further define the relationship between GP I/b-IHa and tyrosine phosphorylation. GP libIRa activation was monitored both by aggregometry and by a sensitive flow cytometric technique that measures the binding of an mAb specific for the activated conformation of GP lib-IRa. Tyrosine phosphorylation was studied using immunoblots probed with an affinity-purified polyclonal antiphosphotyrosine antibody. We demonstrate here that activation of GP lib-IRa and fibrinogen binding to GP fib-IRa are required, but not sufficient, for tyrosine phosphorylation of three specific platelet proteins with apparent molecular masses of 84, 95, and 97 kD. The phosphorylation of these proteins also requires platelet aggregation.
Materials and Methods

Isolation of Platelets
Venous blood was collected from healthy drug-free volunteers and anticoagulated with 0.01 vol 40% sodium citrate or 0.15 vol NIH Formula A acid-citrate-dextrose solution. Platelet isolation was carried out at room temperature. Platelet-rich plasma was obtained by centrifilgation of whole blood at 180 g for 20 rain. After addition of 1 /tM prostaglandin Et (PGE1), platelets were separated from plasma by gel-filtration (Tangen et al., 1971 ) over a Sepharose-2B column equilibrated with an incubation buffer containing 137 mM NaC1, 2.7 mM KC1, 1 mM MgC12, 5.6 mM gincose, 1 mg/ml BSA, 3.3 mM NaH2PO4, and 20 mM Hepes (Sigma Chemical Co., St. Louis, MO), pH 7.4. Gel-filtered platelets were counted in an electronic particle counter (Coulter Electronics, Hialeah, FL) and adjusted to a concentration of 1-3 x l0 s platelets/ml with incubation buffer.
Activation of Gel-filtered Platelets
Immediately after gel filtration, 200 ~M CaC12 was added to the platelet suspension and platelets were stimulated for 1 rain at 37°C with bovine c~-thrombin (1 U/mi; Chrono-Log, Havertown, PAL collagen (5 /zg/mi; Chrono-Log), ADP or a combination of ADP and epinephrine (10 ~tM each; Chrono-Log), phorbol 12-myristate 13-acetate (100 nM; Sigma Chemical Co.), A23187 (1 ;tM; Sigma Chemical Co.), or mastoparan (50 ttM; Sigma Chemical Co. or an HPLC-purified preparation; gift from Elliott Boss [University of Texas Southwestern Medical Center, Dallas, TX]; Higashijima et al., 1988) . In the case of ADP and epinephrine, purified human fibrinogen (50/~g/ml) was also added to support platelet aggregation when the suspensions were stirred (Bennett and Vilaire, 1979) . In the case of the other agonists, sufficient fibrinogen was released from platelet alpha-granules to support the aggregation of stirred platelets. As specified in each experiment, incubations were carried out either without stirring (to prevent aggregation) or in the presence of a magnetic stir bar rotated at 1,000 rpm.
In some experiments, the binding of fibrinogen to GP Iro-Illa was prevented by incubating the gel-filtered platelets with either the tetrapeptide RGDS (500/~M; Sigma Chemical Co. or Peninsula Laboratories, Belmont, CA), 10 mM EDTA, or the anti-GP Ilb-IIIa mAb; A2A9 (50-100 ;~g/mi) (Bennett et al., 1983) for 2 min before the addition of an ngonist. In other experiments, platelets in plasma were preincubated with 10 mM EGTA for 90 rain at either 20 ° or 37°C, and then equimolar CaC12 was added back just before gel filtration. EGTA treatment at 37°C disrupts the integrity of the GP Hb-IHa complex and renders it incompetent to bind fibrinogen or support aggregation even after the addition of equlmolar CaCl2 (Brass et al., 1985; Fitzgerald and Phillips, 1985; Shattil et al., 1985b; Pidard et al., 1986) . As a control, some platelets were preincuhatnd with EGTA at 20°C, a condition that does not disrupt GP Hb-Ilga (Shatfil et al., 1985b; Pidard et al., 1986) . In some experiments, the blood donor ingested 650 mg of aspirin 24 and 2 h before venepuncture to inhibit arachidonic acid metabolism through the cyclooxygenase pathway (Burch et al., 1978) . To insure virtually complete inhibition of cyclooxygenase, experiments with these gelfiltered platelets were carried out in the presence of 10 p.M indomethacin (Sigma Chemical Co.). In some experiments, the gel-filtered platelets were incubated with the cell-permeable calpain inhibitor E64d (100 mg/mi) (McGowen et al., 1989) for 5 min at 250C before thrombin stimulation. Calpain inhibition was assayed by visualization of the total protein profile after staining the gels with Coomassie blue.
Measurement of Platelet Aggregation and Dense Granule Secretion
Platelet aggregation and secretion of dense granule ATP were monitored using a single channel lumi-aggregometer (model 400-VS; Chrono-Log) (Charo et al., 1977; Feinman et al., 1977) . All samples were stirred for one minute unless otherwise stated. The extent of platelet aggregation in each sample was arbitrarily expressed relative to the aggregation of platelets simuhaneously treated with 1 U/mi thrombin. For platelet samples in which no aggregation was apparent in the lumi-aggregometer, a small aliquot was examined by phase-contrast microscopy to determine the extent of formation of very small platelet aggregates (ranging from doublets to aggregates of 25-50 platelets). Platelet ATP secretion was quantitated by arbitrarily settint the luminescence of untreated platelet suspensions at 0 % and thrombintreated platelet suspensions at 100%.
Measurement of GP lib-Ilia Activation and Platelet
Alpha-Granule Secretion
Five murine mAbs were used in these studies. The antibody PACI is specific for the activated form of GP IFo-I~ and binds to a fibrinogen binding site on GP Hb-HIa (Shattil et al., 1985a; Tanb et al., 1989) . Antibody A2A9 binds to both the non-activated and activated forms of GP Hb-HIa and therefore was used to quantitate total surface-expressed GP Ilb-nh (Bennett et al., 1983) . BIB5 is an antibody specific for OP Ilb and SSA6 an antibody specific for GF HIa (Silver et al., 1987) . Antibody S12, specific for the platelet alpha-granule membrane protein, GMP-140, was a gift from Dr. Rodger P. McEver (Oklahoma Medical Research Foundation, Oklahoma City, OK). This antibody binds selectively to platelets that have undergone alpha-granule secretion (McEver and Martin, 1984) . All antibodies were directly conjugated with FITC to a final flnorescein/protein ratio of 2.5-4.0 (Shattil et al., 1987) .
Antibody binding to platelets was assessed by flow cytometry. Unstirred gel-filtered platelets were first incubated for 1 rain at 37°C in the presence or absence of a platelet ngonist. Then, aliquots (1 x 106 cells) were incubated an additional 10 min at 22°C in a total volume of 50/~1 with a saturating concentration of each of the FITC-labeled antibodies (Abrams et al., 1990) . After dilution of each sample to 500 ~1 with PBS, platelets were analyzed in a FACStar (Bectun-Dicklnson Co., Oxnard, CA) flow cytometer as described previously (Shattil et al., 1987; Abrams et el., 1990) . Antibody binding was expressed in arbitrary fluorescence units as the mean fluorescence intensity of 10,000 platelets. This value for antibody binding is directly proportional to the number of antibody molecules bound per platelet (Shattii et al., 1987) .
Figure L Agonist-induced tyrosine phosphorylation of platelet proteins. (a) As described in Materials and Methods, stirred gel-filtered platelets were treated with mastoparan (50 ttM; lane 1), collagen (5 ~g/ ml; lane 2), no agonist (lane 3), ADP (10 t~M; lane 4), ADP plus epinephrine (10 /zM each; lane 5), and thrombin (1 U/ml; lane 6). Platelets were then solubilized with SDS, subjected to SDS-PAGE, and transferred to nitrocellulose filter paper. The immunoblots were incubated with antiphosphotyrosine antibodies. The values below the immunoblot represent percent aggregation and ATP secretion relative to the thrombin-treated sample. Thus, values >100% indicate that a particular sample aggregated or secreted to a greater extent than the thrombin-treated sample. The value of 0% indicates that there was no aggregation or ATP secretion detected as assessed by the lumi-aggregometer. The aggregation and secretion data are expressed relative to the thrombin-treated sample, which was arbitrarily used as a reference index for the induction of tyrosine phosphorylation. (b) Gel-filtered platelets treated with thrombin (1 U/ml; lane 1 ), no agonist (lane 2), forskolin (50 ttg/ml; lane 3), and forskolin and thrombin (lane 4) were prepared and immunoblotted as above. The numbers below the immunoblot represent aggregation and ATP secretion relative to the thrombin-treated sample.
Identification of Phosphotyrosine-containing Platelet Proteins by lmmunoblotting
After activation of gel-filtered platelets for 1 min at 37"C as described above, the cells were sedimented for 4 s at 12,000 g in a microcentrifuge, solubilized in lysis buffer (2 % SDS, 0.39[ 2-mereaptoethanol, 66 mM Tris-HC1, pH 7.5, 10 mM EI3q'A) and heated at 95"C for 10 min. Immunoblot assays were performed as described (Yonemoto et al., 1987) . The immunoblots were incubated with an afffinity-purified rabbit antibody to phosphotyrosine (lot 903; a gift from Dr. Jean Wang [University of California, San Diego]). This antibody has been shown to be specific for phosphotyrosine residues (Wang, 1985; Morla and Wang, 1986) . The binding of this antibody was detected using 125I-labeled donkey anti-rabbit immunoglobulins (Amersham Corp., Arlington Heights, IL). 125I-labeled protein bands were quantitated by densitometric scanning of the autoradiograms with a computing densitometer (Molecular Dynamics, Sunnyvale, CA). Fig. 1 a shows an autoradiographic profile of platelet proteins phosphorylated on tyrosine residues 1 rain after the addition of agonists to a suspension of gel-filtered platelets stirred at 370C. Strong physiological agonists such as thrombin or collagen reproducibly induced the phosphorylation of three proteins with apparent molecular masses of 84, 95, and 97 kD. Weak agonists such as ADP, or ADP in combination with epinephrine, also evoked this response in stirred platelets provided that fibrinogen (50 t~g/ml) had been added to the incubation medium. This pattern of phosphorylation was also observed when stirred platelets were incubated with agonists that circumvent the normal receptor-mediated pathways of cell activation: mastoparan, a peptide from wasp venom that directly activates G proteins, (Hirai et al., 1979) ; (Fig. 1 a) and phorbol 12-myristate 13-acetate, which directly activates protein kinase C (Nishiznka, 1986) ; data previously shown in Golden and Brugge, 1989 . Forskolin, an inhibitor of platelet activation that acts by raising the intracellular concentration of cAMP (Feinstein et al., 1983) , prevented the changes in tyrosine phosphorylation induced by thrombin (Fig. 1 b) and collagen (data not shown). Thus, it appears that an identical set of proteins is phosphorylated on tyrosine residues in stirred platelets within a minute of stimulation by a variety of agonists. This observation suggests that these phosphorylation events are linked to some common platelet activation process and not coupled solely to a single agonist receptor.
Results
Effect of Platelet Activation on lyrosine Phosphorylation of Platelet Proteins
In the experiments shown in Fig. 1 , the platelets were activated under conditions in which both aggregation and secretion occurred. Specifically, the platelets were stirred in the presence of fibrinogen and calcium. For ADP and epinephrine treatment, fibrinogen had been added to the platelet suspension. For the other agonists, sufficient fibrinogen was released from platelet alpha-granules to support aggregation. Indeed, platelet aggregation, ATP secretion from platelet dense granules (Fig. 1) , and alpha-granule secretion (as measured by platelet binding of the anti-GMP-140 antibody, FITC-S12; data not shown) were observed in response to all Figure 2 . Disruption of the GP fib-IRa complex inldbits agonist-induced tyrosine phosphorylation. (a) Platelet-rich plasma was treated without EGTA (Control; lanes 1-3), treated with 10 mM EGTA at 20°C for 90 minutes (lanes 4-6), or treated with 10 raM EGTA at 37°C for 90 min (lanes 7-9) before the addition of equimolar calcium and gel filtration. The gel-filtered platelets were then incubated without agonist (lanes 1, 4, and 7), or with ADP and epinephrine (10 ~M each; lanes 2, 5, and 8), or thrombin (1 U/ml; lanes 3, 6, and 9). Lysates were prepared and immnnoblotted as described in Fig. 1 . The values below the immunoblot represent aggregation and ATP secretion relative to the thrombin-treated sample for the control platelets incubated without EGTA. (b) Effect of EGTA and temperature on agonist-induced PAC1 and S12 binding to platelets. Antibody binding to platelets was assessed by flow cytometry as described in sine phosphorylation of the 84-, 95-, and 97-kD proteins (Fig. 2 a, lane 8) . In contrast, pretreatment of platelets with EGTA at 20°C, which does not disrupt the integrity of GP llb-HIa, did not affect the subsequent binding of FITC-PAC1, platelet aggregation, or tyrosine phosphorylation induced by ADP and epinephrine (Fig. 2 a, lane 5, and Fig. 2 b) . Pretreatment of platelets with EGTA at 37°C disrupts surface GP llb-IIIa, but does not affect internal pools of GP fib-Ilia, which become surface-expressed after thrombinstimulation and which support aggregation (Woods et al., 1986) . Consistent with this observation, we found that such thrombin-stimulated platelets bound FITC-PAC1, aggregated, and underwent agonist-induced tyrosine phosphorylation, although each of these responses was only about 30 % the level of control platelets (Fig. 2, a and b) .
In contrast, pretreatment with EGTA at 37°C did not irapair thrombin-induced dense granule secretion (ATP release) or alpha-granule secretion (FITC-S12 binding; Fig. 2  b) . Together, these data suggest that tyrosine phosphorylation requires a structurally intact form of GP fib-HIa that is capable of activation by agonists. Figure 4 . Agonist-stimulated platelets display minimal changes in tyrosine phosphorylation unless they are stirred and aggregate. Gelfiltered platelets were treated with thrombin (1 U/ml; lanes 1 and 3), 500 #M RGDS and thrombin (lanes 2 and 4), or no agonist (lane 5). The platelets in lanes 3 and 4 were not stirred upon addition of agonists. All these samples were prepared and immunoblotted as described in Fig. 1 . The values below the immunoblot represent aggregation and ATP secretion relative to the thrombin-treated sample.
agonists tested. These results suggest that tyrosine phosphorylation of the 84-, 95-, and 97-kD proteins is induced by some component of stimulus-response coupling that is linked to platelet aggregation and/or granule secretion. The following experiments were performed to explore the relationship between tyrosine phosphorylation and events leading to platelet aggregation.
Relationship of 2)~osine Phosphoryiation to Platelet Responses Mediated by GP IIb-IIIa
The process of platelet aggregation requires the activation of GP Hb-lIIa, resulting in exposure of binding sites for fibrinogen. This event is followed by fibrinogen binding and, provided that the cell suspension is stirred, platelet aggregation. To assess whether GP lTo-rlla activation was necessary for the agonist-induced tyrosine pbosphorylation pattern shown in Fig. 1 , platelets in plasma were initially incubated with 10 mM EGTA at 37°C for 90 rain, CaC12 (10 raM) was then added, and the platelets were gel filtered. This treatment results in the irreversible disruption of surface GP lib-Ilia and the failure of GP lib-Ilia activation by ADP and epinephrine (Brass et al., 1985; Fitzgerald and Phillips, 1985; Shattil et al., 1985b; Pidard et al., 1986) . Incubation with EGTA at 37°C prevented ADP and epinephrineinduced aggregation (Fig. 2 a, lane 8) , and inhibited the binding to platelets of FITC-PAC1, an mAb specific for the activated form of GP llb-IHa (Fig. 2 b) . It also caused a significant reduction in ADP and epinephrine-induced tyro- Figure 5 . Inhibition of platelet cyclooxygenase does not inhibit agonist-induced tyrosine phosphorylation. Gel-filtered platelets isolated from donors who had ingested aspirin were incubated with l0 pM indomethacin to further insure complete inhibition of arachidonic acid metabolism. The platelets were then treated with thrombin (1 U/m]; lane I), 100 izg/rrd antibody A2A9 and thrombin (lane 2), no agonist (lane 3), ADP and epinephrine (10 ~tM each; lane 4), or A2A9, ADP, and epinephrine (lane 5), and prepared and immunoblotted as described in Fig. 1 . The values below the immunoblot represent aggregation and ATP secretion relative to the thrombin-treated sample. In platelets from donors not treated with aspirin, indomethacin did not cause a reduction in thrombininduced tyrosine phosphorylation of the 84-, 95-, and 97-kD proteins (data not shown). Figure 6 . Inhibition of platelet calpain does not inhibit agonistinduced tymsine phosphorylation. (a) Coomassie blue-stained gel of lysates from gel-filtered platelets that had been incubated without agonist (lane 1), or with thrombin (1 U/ml; lane 2), or with E64d (100 mg/ml) for 5 min at 25°C before thrombin addition (lane 3). The three anx~he, ads at top point to talin, aetin-binding protein, and myosin heavy chain. The lower three arrowheads point to the degradation products of myosin heavy chain (135 kD) and of actinbinding protein (93 kD) which are only apparent in lane 2. (b) Gelfiltered platelets were incubated as described in a and prepared and immunoblotted as described in Fig. 1 .
Since activation of GP Wo-IHa and fibrinogen binding to GP l/b-Ilia are closely related, but sequential events, we then asked whether tyrosine phosphorylation was dependent on fibrinogen binding to GP lib-Ilia. To address this question, platelets were stimulated with thrombin in the presence of either the tetrapeptide, RGDS, the divalent cation chelator, EDTA, or the mAb A2A9. Each of these agents is known to prevent fibrinogen and PAC1 binding to activated GP llb-llla (Bennett and Vilaire, 1979; Bennett et al., 1983; Gartner and Bennett, 1985) . None of these inhibitors affected the basal pattern of tyrosine phosphorylation when incubated in the absence of agonlsts (Fig. 3 a, lanes 2, 6, and 10) . However, each agent inhibited thrombin-induced FITC-PAC1 binding by 70-95% (Fig. 3 b) , aggregation by >80%, and thrombininduced tyrosine phosphorylation of the 84-, 95-, and 97-kD proteins by ,x,90% (Fig. 3 a) . Similar results were obtained when platelets were stimulated with ADP and epinephrine in the presence of these inhibitors (data not shown). Control monoclonal antibodies specific for GP fib (B1B5) or GP Ilia (SSAt), which do not inhibit fibrinogen binding, had no effect on thrombin-induced PAC1 binding, platelet aggregation, or tyrosine phosphorylation (data not shown).
Although RGDS, EDTA, and A2A9 severely reduced platelet aggregation and agonist-induced tyrosine phosphorylation, these agents had no effect on thrombin-induced alpha-granule secretion (platelet binding of FITC-S12; Fig.  3 b) or dense granule secretion (ATP release; Fig. 3 a) . These data indicate that the induction of tyrosine phosphorylation requires the agonist-induced binding of fibrinogen to GP l/b-Ilia. They also suggest that tyrosine phosphorylation of this set of proteins is not required for platelet secretion in response to thrombin.
In separate experiments, induction of tyrosine phosphorylation was not observed when platelets were stimulated to agglutinate in the presence of von W'dlebrand factor, ristocetin, and EDTA (data not shown). Under these conditions, platelets clump together in a process that requires the binding of von Wfllebrand factor to GP Ib and is independent of GP libIlia (Zucker et al., 1977) .
To examine whether platelet aggregation was required for tyrosine phosphorylation, platelets were activated by thrombin or ADP plus epinephrine in the absence of stirring. Under these conditions, GP llb-IHa is activated and is capable of binding PAC1 (see Fig. 3 , a and b) and fibrinogen (Bennett et al., 1979) , and aggregation is prevented. In the absence of stirring, platelets exhibited only a minimal level of agonist-induced tyrosine phosphorylation of the 84-, 95-, and 97-kD proteins when compared with stirred thrombin-treated platelets ( Fig. 4; compare lanes I and 3) . Collectively, these studies demonstrate that the induction of tyrosine phosphorylation requires GP l/b-IIIa activation, fibrinogen binding, and fibrinogen-dependent platelet aggregation.
Relationship of 1~yrosine Phosphorylation to Platelet Events Subsequent to Aggregation
Since phosphorylation of the 84-, 95-, and 97-kD proteins was inhibited under conditions that blocked the process of platelet aggregation, we considered the possibility that activation of tyrosine phosphorylation was induced by some platelet response that is dependent upon platelet aggregation. Although the events that follow platelet aggregation are not completely understood, three such responses have been clearly identified: (a) conversion of arachidonic acid to thromboxane A2, (b) granule secretion (when platelets are stimulated with ADP or epinephrine), and (c) activation of platelet calcium-dependent proteases (calpains). To examine whether tyrosine phosphorylation required arachidonic acid metabolism and granule secretion, platelets were pretreated with aspirin and indomethacin to inhibit cyclooxygenase. Since platelet secretion by ADP and epinephrine is mediated by arachidonic acid metabolites, blockade of cyclooxygenase prevents granule secretion. Platelets treated with aspirin and indomethacin underwent primary wave aggregation in response to ADP and epinephrine when stirred in the presence of fibrinogen. Under these conditions, dense granule secretion (ATP release) was completely inhibited (Fig. 5) . Aspirin and indomethacin did not prevent the tyrosine phosphoryla- The plus symbol refers to a cellular response 975% of maximal; the minus symbol refers to a cellular response ~30% of maximal.
tion of the 84-, 95-, and 97-kD proteins induced by ADP and epinephrine (Fig. 5) . Thus, neither arachidonic acid metabolism nor platelet dense granule secretion appear to be absolutely necessary for the induction of tyrosine phosphorylation. The reduced level of tyrosine phosphorylation in ADP/ epinephrine treated platelets (lane 4) could be a consequence of the inhibited secretion of factors that potentiate the aggregation response. Activation of platelet calpains requires platelet aggregation (Fox, 1987; Weidmer et al., 1990) . Calpain activation can be monitored indirectly on Coomassie blue-stained SDS gels as a decrease in the amount of the calpain substrates, actin-binding protein (270 kD), talin (235 kD), and myosin heavy chain (200 kD) and as a concomitant increase in the degradation products of actin-binding protein (190 and 93 kD), talin (190 kD) , and myosin heavy chain (135 kD) (Fig.  6 a) . However, when stirred platelets were stimulated with thrombin in the presence of E64d, a cell permeable inhibitor of calpains (McGowen et al., 1989) , no evidence of calciumdependent protease activity could be detected (Fig. 6 a) . Furthermore, E64d treatment had no effect on platelet aggregation or the induction of tyrosine phosphorylation of the 84-, 95-, and 97-kD proteins (Fig. 6 b) .
Discussion
These studies demonstrate that activation of platelets by a variety of agonists induces tyrosine phosphorylation of three proteins with apparent molecular masses of 84, 95, and 97 kD. Since two-dimensional immunoblot analysis has not been performed, the exact number of phosphoproteins represented by these three bands is unknown. This pattern of phosphorylation was observed whether platelets were stimulated in a receptor-mediated fashion by thrombin, collagen, or ADP and epinephrine, or in a receptor-independent fashion by an activator of G proteins (mastoparan) or protein kinase C (phorbol ester). Using a variety of experimental systems and monitoring techniques, we established that this pattern of tyrosine phosphorylation is dependent on agonistinduced activation of GP Ilb-llIa, fibrinogen binding to GP IIb-IIIa, and platelet aggregation. In contrast, platelet arachidonic acid metabolism, dense granule secretion, and calpain activity are not necessary for tyrosine phosphorylation of these proteins. Table I summarizes the experimental support for these conclusions.
Upon platelet activation, the surface membrane GP nbIIIa complex undergoes a conformational change that permits it to function as a receptor for adhesive ligands, including fibrinogen, yon Willebrand factor, and under some circumstances, fibronectin (Plow and Ginsberg, 1989) . In plasma, fibrinogen is the dominant ligand (Pietu et al., 1984; Gralnick et al., 1984; Schullek et al., 1984) . The binding of fibrinogen and RGD-contalning peptides to GP I/b-INa has been shown to induce clustering of GP lTo-Ma complexes within the plane of the plasma membrane (Isenberg et al., 1989) . In the present study, RGDS binding per se did not induce tyrosine phosphorylation in platelets, suggesting that clustering of GP lIb-llla complexes is not sufficient to induce tyrosine phosphorylation. However, the experiments illustrated in Fig. 2 in which agonist-induced tyrosine phosphorylation was inhibited by preincubating platelets with EGTA at 37°C indicated that the functional integrity of GP lib-Ilia is required for these tyrosine phosphorylation events.
Fibrinogen binding to activated GP nb-Ma and platelet aggregation can be inhibited by RGD-containing peptides, by chelation of divalent cations, and by certain anti-GP llb-lIIa mAbs (Gartner and Bennett, 1985; Plow et al., 1985; Ben-nett et al., 1983; Shattil et al., 1986) . The experiments in which fibrinogen binding and aggregation were inhibited by RGDS, EDTA, or mAb A2A9 (Fig. 3) suggested that agonist-induced tyrosine phosphorylation required the binding of fibrinogen to GP fib-IRa. Although unstirred platelets stimulated by agonists displayed evidence of GP fib-IRa activation (FITC-PAC1 binding), they did not display the inducible pattern of tyrosine phosphorylation (Fig. 4) , implying that platelet aggregation was necessary for these phosphorylation events to occur. Platelet agglutination by ristocetin and von Willebrand factor, a process that involves GP Ib and not GP fib-IRa, did not induce tyrosine phosphorylation. Thus, these studies clearly indicate that GP fib-IRa activation and fibrinogen binding are necessary for tyrosine phosphorylation, but these events are not sufficient. Rather, once fibrinogen has become bound to activated platelets, the platelets must aggregate in order for the induction of tyrosine phosphorylation to occur.
We obtained substantial evidence that dense granule secretion is not required for tyrosine phosphorylation of the 84-, 95-, and 97-kD proteins and that secretion of dense and alpha granules is not dependent on tyrosine phosphorylation of these proteins. Pretreatment with aspirin and indomethacin, which blocked arachidonic acid metabolism and granule secretion, did not inhibit the induction of tyrosine phosphorylation by ADP and epinephrine (Fig. 5 ). In addition, stirred platelets underwent full thrombin-induced granule secretion under conditions where platelet aggregation and tyrosine phosphorylation were blocked by RGDS, EDTA, or the mAb A2A9 (Fig. 3) . Finally, unstirred platelets exhibited normal granule secretion when stimulated with thrombin, but they did not aggregate or undergo agonist-induced tyrosine phosphorylation (Fig. 4) . It is also likely that tyrosine phosphorylation is unrelated to agonist-induced platelet shape change, the process whereby the cell undergoes spheration and pseudopodial extension. Unstirred platelets or platelets in EDTA can undergo shape change in response to thrombin or ADP (Siess, 1989) ; however, agonist-induced tyrosine phosphorylation was barely detectable under these conditions.
The observation that fibrinogen binding to GP fib-IRa is necessary for the induction of tyrosine phosphorylation is consistent with the recent findings of Ferrell and Martin (1989) who demonstrated that RGDS inhibited thrombininduced tyrosine phosphorylation of proteins of Mr 126,000, 108,000 and 100,000, and that these proteins are not phosphorylated in thrombasthenic platelets which lack GP fibIRa. The antiphosphotyrosine antibodies used in this study detected several additional thrombin-induced proteins that were not sensitive to RGDS, suggesting that all thrombininduced tyrosine phosphorylation events are not dependent on fibrinogen binding. Our results and conclusions differ in two respects to those of Ferrell and Martin. First, although Ferrell and Martin observed an induction of tyrosine phosphorylation in response to thrombin, they did not detect such phosphorylation when platelets were stimulated with ADP in the presence of fibrinogen. They concluded that ADPinduced activation of GP fib-IRa and aggregation were insufficient to induce the tyrosine phosphorylation of proteins in the 100-kD range. However, we observed that ADP or ADP and epinephrine could activate GP fib-IRa and induce both aggregation and tyrosine phosphorylation. Technical considerations may explain this apparent discrepancy. In the study of Ferrell and Martin, platelets were washed by repeated centrifugation rather than gel filtration. It is difficult to avoid inadvertent platelet activation when platelets are washed by centrifugation. Platelets partially activated during the washing process may become relatively refractory to subsequent stimulation by agonists (Peerschke, 1985) . Indeed, Ferrell and Martin did not observe tyrosine phosphorylation of proteins in the 100-kD range until 3-5 min after thrombin stimulation, while we have observed this pattern within 30 s of stimulation (Golden and Brugge, 1989) .
The second difference between our findings and those of Ferreli and Martin is that we found that induction of tyrosine phosphorylation was dependent on stirring the suspension of activated platelets. We concluded that GP IFo-iRa, fibrinogen binding to GP fib-IRa, and platelet aggregation are necessary for induction of tyrosine phosphorylation. In contrast, FerreU and Martin concluded that "GP llb-IRa-ligand interaction per se, and not aggregation", was required for the induction of tyrosine phosphorylation. Again, technical considerations may explain this discrepancy. It is difficult to avoid platelet microaggregation when platelets are centrifuged, washed, and then incubated with thrombin. Indeed, we have found that when some degree of tyrosine phosphorylation is observed in a platelet sample believed to contain no aggregates, as determined in a conventional platelet aggregometer, microscopic platelet aggregates are invariably present.
What is the exact relationship between tyrosine phosphorylation and platelet aggregation? It is possible that agonist-induced tyrosine phosphorylation is necessary for an event that follows fibrinogen binding to GP fib-IRa and that is required for the process of aggregation. These "postoccupancy" events remain to be characterized, however, the ability of desensitized platelets to bind fibrinogen normally (in the absence of aggregating) suggests that fibrinogen binding is not sufficient for full platelet aggregation (Peerschke, 1985; Shattil et ai., 1986) . Alternatively, tyrosine phosphorylation may be involved in some cellular process that is dependent on platelet aggregation (i.e., activation of the Na+/H * pump). Although further studies will be required to establish more precise cause-effect relationships, the present studies clearly establish that induction of tyrosine phosphorylation does not require platelet arachidonic acid metabolism or dense granule secretion. In addition, expe "rnnents using the cell permeable calpain inhibitor, E64d, imply that tyrosine phosphorylation does not require caipain activation.
Platelet aggregation is associated with a structural reorganization of the platelet cytoskeleton that is correlated with the physical association of GP fib-Ilia with one or more Triton-insoluble cytoskeletai elements (Phillips et al., 1980) . Recent studies suggest that activated GP fib-iRa may become associated with a specific cytoskeletai protein, talin Beckerle et ai., 1989) . Although the precise role of such interactions is speculative, they might be involved in GP fibIRa-mediated adhesion of platelets to the subendothelial matrix (Weiss et ai., 1989) or in clot retraction (Cohen et al., 1989) . A direct or indirect association of GP fib-IRa with a protein-tyrosine kinase could be one means by which such functions are regulated. In other cells, protein-tyrosine kinases can induce alterations in the organization of the membrane cytoskeleton. These kinases include the epidermal growth factor receptor (Schlessinger and Geiger, 1981) , the platelet-derived growth factor receptor (Herman and Pledger, 1985) , and the viral src (David-Pfeuty and Singer, 1980), yes (Gentry and Rohrschneider, 1984) , abl (Rohrschneider and Najita, 1984), andfps (Tarone et al., 1985) gene products.
These speculations raise the question as to whether the GP Hb-IIIa complex might communicate with a protein-tyrosine kinase. Despite the high levels of the c-src gene product in platelets (0.2% of total cell protein [Golden and Brugge, 1989 ]), there is as yet no evidence that this protein associates with GP IIb-HIa or is the kinase responsible for the agonistinduced tyrosine phosphorylation of the 84-, 95-, and 97-kD proteins (Ferrell and Martin, 1988; Golden and Brugge, 1989) . Recently, the CD4 and CD8 receptors of helper and cytotoxic T-lymphocytes have been shown to associate with and regulate a src-related protein-tyrosine kinase, p56 ~ (Veillette et al., 1988) . Thus, the coupling of cell surface receptors with protein-tyrosine kinases could represent a common mechanism for mediating signal transduction events triggered by cell-cell, and perhaps cell-matrix interactions.
The identifies of the 84-, 95-, and 97-kD tyrosinephosphorylated proteins in agonist-stirnulated platelets are unknown. Although the 95-and 97-kD proteins are similar in apparent molecular weight to nonreduced GP HIa, preliminary immunoblotting and immunoprecipitation studies suggest that neither of these proteins represents GP llla (Ferrell, J., and G. S. Martin, personal communication; S. Nemeth, L. Lipfert, A. Golden, and J. S. Brugge, personal observation). Identification of these proteins and their functions will be facilitated by their isolation and by analysis of their primary structure.
